Try our Advanced Search for more refined results
Life Sciences
-
February 03, 2026
Trump Admin Sued Over 'Pay-To-Play' Gold Card Program
Immigrants and an academic professionals union filed suit Tuesday to block President Donald Trump's "gold card" visa program, telling a D.C. federal court that the "pay-to-play" program unlawfully takes visas away from professionals the existing employment-based visa system prioritizes.
-
February 03, 2026
Medical Transport Co. Misclassified Drivers, Suit Says
A company that transports radioactive medical materials misclassified drivers as independent contractors, leading to minimum wage and overtime violations, according to a proposed class and collective action filed in Florida federal court.
-
February 03, 2026
Novartis, Sandoz Face New Generic-Drug Price-Fixing Suit
Adding to sprawling antitrust litigation against pharmaceutical giants, 42 states and territories sued Novartis AG, Sandoz AG and other drug companies in Connecticut federal court Monday, alleging that the companies colluded for years to fix prices and control markets for generic drugs.
-
February 03, 2026
Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says
A clinical trial services company is suing Definium Therapeutics Inc. in Delaware federal court, alleging that it stole trade secrets during Phase 2 trials of LSD treatments for psychiatric disorders, then passed those secrets on to a rival services company for Phase 3 trials.
-
February 03, 2026
Amway Looks To Sidestep Gut Drink Trademark Fight In NC
Multi-level marketing giant Amway is seeking an early exit from a trademark infringement suit brought by a supplement maker in North Carolina, saying it has no ties to the Tar Heel state sufficient to be dragged into court there.
-
February 03, 2026
Alston & Bird Adds Healthcare Regulatory Pro From Goodwin
Alston & Bird LLP has added a healthcare regulatory attorney previously with Goodwin Procter LLP as a partner in Chicago, the firm announced Tuesday.
-
February 02, 2026
Wheeling & Appealing: The Latest Must-Know Appellate Action
What happened to a GOP donor's $250,000 Swiss watch? Can cigarette warnings show jarring medical images? Will a circuit split of "far-reaching importance" for arbitration get even wider? That's a taste of the oral argument menu we'll help you digest in this preview of February's top appellate action.
-
February 02, 2026
'Terumo Knew' Of Dangerous Emissions, Jury Told
A pollution expert witness told a Colorado jury Monday in the latest trial over Terumo's alleged emissions of toxic ethylene oxide that the medical sterilizer was fully aware of the community emissions and their danger.
-
February 02, 2026
'Star Trek'-Citing Judge Says Moderna Can't Ax $5B Vax IP Suit
Moderna Inc. will have to face most of a rival mRNA vaccine developer's $5 billion patent suit over the company's COVID-19 vaccines at a trial in Delaware, a federal judge ruled on Monday, invoking "Star Trek" in a summary judgment order that left issues like patent invalidity up to the jury.
-
February 02, 2026
Monthly Merger Review Snapshot
U.S. enforcers reached three new merger settlements, while the Federal Trade Commission successfully blocked a $945 million heart valve deal and lodged an appeal for its case targeting Meta's past acquisitions.
-
February 02, 2026
PTAB Sinks Samsung Challenge To Ouraring Patent
The Patent Trial and Appeal Board has shot down Samsung Electronics Co. Ltd.'s challenge to an Ouraring Inc. smart ring patent amid an ongoing legal dispute that has spanned the board, federal district court and the U.S. International Trade Commission.
-
February 02, 2026
1st Circ. Judge Wary Of Boston Bid To Revive PBM Opioid Suit
The city of Boston faced pushback from a First Circuit judge on Monday as it argued it didn't miss its window to sue pharmacy benefit managers for their alleged role in the opioid epidemic.
-
February 02, 2026
DLA Piper Adds Ex-Cooley Atty To Lead N. Calif. Practice
DLA Piper announced Monday that it has added the former global chair of Cooley LLP's digital health group to lead its Northern California corporate and securities practice and bolster its capacity to advise life sciences and technology companies on transactions and other matters.
-
February 02, 2026
Mintz Adds Winston & Strawn ITC Practice Co-Leader In DC
Mintz Levin Cohn Ferris Glovsky and Popeo PC has grown its Washington, D.C., office by bringing a Winston & Strawn LLP equity partner as its International Trade Commission practice co-chair, strengthening the firm's intellectual property services with a patent litigator with two decades of experience.
-
February 02, 2026
Bausch, Lannett To Pay $17.9M In Drug Price-Fixing Deal
Lannett Company Inc., Bausch Health US LLC and Bausch Health America Inc. will pay $17.85 million to settle allegations by 48 states and territories that they conspired to fix prices for generic drugs, according to a motion filed Monday seeking preliminary approval of the deal.
-
January 30, 2026
3rd Circ. Preview: Privacy Issues Top Feb. Argument Lineup
Issues involving privacy feature prominently on the Third Circuit's February oral argument schedule, with panels set to hear a dispute regarding an optometry business's duty to protect private data belonging to third-party customers, and a case over whether the city of Philadelphia can be sued by a mother after a police officer shared images of her son's death from the scene where he committed suicide.
-
January 30, 2026
CBD Cos. Say They're Wrong Defendants In Kratom Suit
Shaman Botanicals LLC and CBD American Shaman LLC are urging a California federal judge to throw out claims that they mislead consumers by failing to warn them that Soma Kratom products are dangerous and addictive, saying they're not affiliated with Soma Kratom in the first place.
-
January 30, 2026
Dozens Of Cases Linking Zantac To Cancer Thrown Out
A Delaware state trial judge tossed over 200 cases by individuals alleging Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, ruling the claims were time-barred.
-
January 30, 2026
Drugmakers Ask To Appeal Overarching Conspiracy Claim
A group of pharmaceutical companies that failed to secure a pretrial win on an overarching conspiracy claim in a sprawling generic-drug antitrust enforcement action is asking a Connecticut federal judge to let them seek Second Circuit review, saying the ruling raises a novel legal issue.
-
January 30, 2026
ThermoLife Asks Justices To Resolve Split Over Sanctions
ThermoLife is asking the U.S. Supreme Court to take up its fight against a lower court's decision to sanction the company and its CEO as part of a false advertising case, saying the Federal Circuit wrongly backed the award.
-
January 30, 2026
Amazon Says Shoppers' Labeling Suit Is Corrupted By AI Errors
In customers' latest filing in their proposed class action accusing Amazon of failing to make required disclosures on dietary supplement product pages, the e-commerce giant alleges that the plaintiffs have submitted a document riddled with errors derived from the use of generative text.
-
January 30, 2026
Drug Cos. Want Rethink Of DQ Bid Targeting Ex-Prosecutor
More than two dozen pharmaceutical companies accused of fixing generic-drug prices have again asked a Pennsylvania federal judge to disqualify a former Connecticut assistant attorney general now in private practice from representing insurers Humana Inc. and Molina Healthcare Inc. in a sprawling multidistrict litigation proceeding.
-
January 30, 2026
AstraZeneca Beats FMLA Suit After Ex-Worker Went Silent
AstraZeneca won't have to face a former employee's lawsuit alleging the pharmaceutical giant fired him for taking medical leave to address his gastrointestinal illness, a Connecticut federal judge ruled, saying he failed to respond to discovery and motions and ignored court orders.
-
January 29, 2026
J&J, Talc Unit Get Patients' Bankruptcy Fraud Claims Tossed
A New Jersey federal judge Thursday tossed a proposed class action brought by cancer patients who allege that Johnson & Johnson's maneuvers to settle thousands of tort claims through Chapter 11 involved fraud, saying the plaintiffs have not asserted an injury that confers standing to sue.
-
January 29, 2026
Conn. Drug Price Cap Survives Distributor Challenge, For Now
The Second Circuit has declined a bid to immediately block the state of Connecticut from enforcing a cap on generic and off-patent drug prices while the Healthcare Distribution Alliance, a collection of wholesale distributors, challenges the new law.
Expert Analysis
-
Series
The Biz Court Digest: Welcome To Miami
After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.
-
Identifying And Resolving Conflicts Among Class Members
As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.
-
Adapting To A Plaintiff-Side Mindset For Patent Monetization
A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.
-
AI Evidence Rule Tweaks Encourage Judicial Guardrails
Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.
-
Series
The Law Firm Merger Diaries: Getting The Message Across
Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.
-
Opinion
Horizontal Stare Decisis Should Not Be Casually Discarded
Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.
-
10 Commandments For Agentic AI Tools In The Legal Industry
Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.
-
Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims
The Federal Circuit's recent decision in Barrette Outdoor Living v. Fortress Iron provides useful guidance on how patent prosecutors should avoid language that triggers specification disclaimer and prosecution disclaimer, doctrines that may be used to narrow the scope of patent infringement claims, say attorneys at Knobbe Martens.
-
New Drug Ad Regs Could Lead To A Less Informed Public
A federal push to mandate full safety warnings in pharmaceutical advertising could make drug ads less appealing for companies to air, which in turn could negatively affect consumers' health decisions by removing an accessible information source, say Punam Keller at Dartmouth College and Ceren Canal Aruoba at Berkeley Research Group.
-
Series
Preaching Makes Me A Better Lawyer
Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.
-
A Look At Middlemen Fees In 340B Drug Discount Program
A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.
-
How Large Patent Damages Awards Actually Play Out
Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.
-
Series
Law School's Missed Lessons: Practicing Client-Led Litigation
New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.
-
Navigating 2025's Post-Grant Proceeding Shakeups
Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.
-
Series
The Law Firm Merger Diaries: How To Build On Cultural Fit
Law firm mergers should start with people, then move to strategy: A two-level screening that puts finding a cultural fit at the pinnacle of the process can unearth shared values that are instrumental to deciding to move forward with a combination, says Matthew Madsen at Harrison.